Related Experiment Videos
Bopindolol: pharmacological basis and clinical implications
T Nagatomo1, Y Hosohata, T Ohnuki
1Department of Pharmacology, Niigata College of Pharmacy, 5-13-2 Kamishinei-cho, Niigata 950-2081, Japan. nagatomo@niigata-pharm.ac.jp
Cardiovascular Drug Reviews
|April 21, 2001
Summary
Bopindolol is a beta-blocker that works on beta 1- and beta 2-adrenoceptors (ARs). Its unique properties suggest potential benefits for treating cardiovascular diseases.
Area of Science:
- Pharmacology
- Molecular Biology
- Cardiovascular Research
Background:
- Bopindolol is a non-selective antagonist of beta 1- and beta 2-adrenoceptors (ARs).
- Understanding its unique pharmacological properties is crucial for cardiovascular disease treatment.
Purpose of the Study:
- To review and summarize the unique properties of bopindolol.
- To explore its potential in treating cardiovascular diseases based on its pharmacological profile.
Main Methods:
- Pharmacological assays
- Molecular biological techniques
- Molecular modeling studies
Main Results:
- Bopindolol exhibits sustained blockade of beta 1- and beta 2-ARs.
- It possesses intrinsic sympathomimetic and membrane stabilizing actions.
- Bopindolol inhibits renin secretion and interacts with 5-HT receptors.
- Molecular modeling identified specific interaction sites with beta-AR subtypes.
- Low affinity for the beta 3-AR subtype was observed.
Conclusions:
- Bopindolol's non-selective antagonism of beta 1- and beta 2-ARs, along with its other properties, supports its potential therapeutic use.
- These pharmacological characteristics indicate bopindolol may be beneficial in managing cardiovascular diseases.